Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors

Author:

Patel Chirag¹,Goel Sanjay²,Patel Manish R.³,Rangachari Lakshmi¹,Wilbur Jayson D.⁴,Shou Yaping¹,Venkatakrishnan Karthik¹,Lockhart A. Craig⁵

Affiliation:

1. Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA

2. Montefiore Medical Center Bronx New York USA

3. Florida Cancer Specialists/Sarah Cannon Research Institute Sarasota Florida USA

4. Metrum Research Group LCC Connecticut USA

5. Sylvester Comprehensive Cancer Center Miller School of Medicine University of Miami Miami Florida USA

Funder

Millennium Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

Reference26 articles.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献